RxDoctor Payments Data

Elizabeth Goodwin, NP

Gastroenterology · Chattanooga, TNNPI 1306834064

Payments from drug & device makers

$13,511in general payments, 2019–2025

Across 656 payments — averaging $20.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Johnson & Johnson$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Daiichi Sankyo Inc.$417
  • Sanofi$405
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$13,18698%
  • Education$2862%
  • Gifts$400%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,511 in reported general payments places this provider in the 75th percentile of 336 gastroenterology providers in Tennessee.

See all gastroenterology providers in Tennessee

Medicare billing

Part B allowed, 2024
$23,943
Medicare patients
174
Services billed
245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase93$347,842
Humira(Cf) PenAdalimumab16$107,109
LinzessLinaclotide93$62,733
ClenpiqSod Picosulf/Mag Ox/Citric Ac49$8,420
SutabSod Sulf/Pot Chloride/Mag Sulf22$3,632
Pantoprazole Sodium272$3,111
Mesalamine15$3,089
Lubiprostone14$2,633
Famotidine141$1,959
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates20$1,107
Sucralfate50$855
Omeprazole50$711
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl47$673
Esomeprazole Magnesium21$665
Dicyclomine Hcl14$378

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$4,200$410,575186 claims
Ferring Pharmaceuticals Inc.Clenpiq$104$8,42049 claims
Braintree Laboratories, Inc.Sutab$107$3,63222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 336 gastroenterology providers in Tennessee.

Other gastroenterology in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →